Methamphetamine Dependency. Mental and behavioural disorders due to psychoactive substance use
Conditions
Interventions
Intervention 1: Intervention: drug will be started at 1200 mg/day and will be raised to 2400 mg/day after 2 weeks, and to 3600 mg/day after 4 weeks, and will be continued until week 6. Intervention 2
Treatment - Drugs
Placebo
Intervention: drug will be started at 1200 mg/day and will be raised to 2400 mg/day after 2 weeks, and to 3600 mg/day after 4 weeks, and will be continued until week 6.
Control: Placebo with numbers equal to main drug in 2 weeks intervals.
Sponsors
Isfahan University of Medical Sciences, Behavioral Sciences Research Center
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1) men and women aged 18–65 years old; 2) informed acceptance to comply with study procedures. Exclusion criteria: 1) sever medical illness that would impair the ability to participate safely in the study; 2) a current neurological or axis I psychiatric disorders not due to substance abuse (e.g., schizophrenia, dementia) that would impair ability to participate safely in the study; 3) current pregnancy or nursing in women; 4) current serious suicidal intention or plan; 5) more than 3 times elevation of AST and ALT at screening; 6) past medical history of asthma or seizures; 7) Subjects who had recently used medications (<14 days) felt to be hazardous if taken with NAC (e.g. carbamazepine, nitroglycerin); and 8) subjects who met DSM-IV criteria for opiates dependence. Also in following conditions the patient will be out of study: 1) incidence of seizure or sever medical illness that would impair ability to participate safely in the study; 2) non compliance or not willing for continuing the study; 3) sever and unbearable drug side effect even after reducing the dose.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Methamphetamine Craving. Timepoint: At screening and every 2 weeks up to 6 weeks. Method of measurement: Cocaine Craving Questionnaire-Brief (CCQ-Brief). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Sharbafchi Zadeh
Department of Psychiatry, Isfahan University of Medical Sciences
Outcome results
None listed